Friday, December 6, 2024
HomeCoronavirusCovishield, Covaxin prices likely to be capped at Rs 275 per dose

Covishield, Covaxin prices likely to be capped at Rs 275 per dose

Date:

Related stories

Fake Electro-Homeopathy Degree Racket Busted in Gujarat: 13 Arrested, 10 Fake Doctors Identified

A fraudulent Bachelor of Electro-Homeopathy Medicine and Surgery (BEMS)...

Gujarat Schools Face Challenges in Generating Apaar IDs Due to Aadhaar Name Discrepancies

Gujarat schools are facing significant challenges in creating Apaar...

Urvil Patel Breaks Record with Fastest T20 Century by an Indian in Syed Mushtaq Ali Trophy

Urvil Patel's Historic Knock Gujarat's wicketkeeper-batter Urvil Patel made history...

Madhya Pradesh CM Mohan Yadav Lauds GIFT City and Gujarat’s Digital Governance Initiatives

Chief Minister Mohan Yadav has emphasized the significance of...

Gujarat CM Bhupendra Patel Inaugurates ‘Bharat Cool’ Festival to Celebrate Indian Culture and Heritage

Gujarat Chief Minister Bhupendra Patel inaugurated the 'Bharat Cool'...
spot_imgspot_img

The prices of Covishield and Covaxin could be capped at Rs 275 per dose, with an additional service charge of Rs 150, once the two Covid-19 vaccines get regular market approval from the drug regulator, a report by news agency Press Trust of India said, quoting official sources.

The National Pharmaceutical Pricing Authority (NPPA) has been asked to start working towards capping the price to make the vaccines affordable, it said.

Currently, Covaxin is priced at Rs 1,200 per dose, while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge.

India has so far vaccinated over 92 per cent of its adult population with one dose, while more than 72 per cent adults are fully vaccinated. More than 80 per cent have received the Covishield dose. According to experts, there are only two market players involved in the case of these two vaccines, unlike drugs where the market price is captured by different data sets.

Covishield and Covaxin are currently in use under emergency use authorisation, which was granted on January 3, 2021. Both vaccines were recommended for full market approval for use in the adult population by a subject expert committee of the Central Drugs Standard Control Organisation on January 19, subject to certain conditions. The recommendations are now being considered by the Drug Controller General of India (DCGI), which is expected to take a call on the matter soon.

The government has indicated that the full market approval for both vaccines could come with certain conditions. In principle, according to experts, such an approval would mean that the vaccine manufacturers can sell in the open market with some price control.

There is lack of clarity on whether market authorisation means the vaccines would be available in chemist shops for the general population to purchase, and if the makers would be allowed to sell them freely.

Prakash Kumar Singh, director, government and regulatory affairs, Serum Institute of India, had submitted an application to the DCGI on October 25, seeking regular market approval for its Covishield vaccine.

Bharat Biotech, too, has submitted complete information on the chemistry, manufacturing and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

LEAVE A REPLY

Please enter your comment!
Please enter your name here